Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S GREENSTEIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1205931789
CMS profile
191041
Location
BEVERLY, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$130,421.20

341 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 341 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S GREENSTEIN

NPI 1205931789 · CMS profile ID 191041

Allopathic & Osteopathic Physicians / Dermatology

BEVERLY, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 341 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205931789?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 341 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205931789?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 341 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205931789?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 341 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1205931789?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

341 matching records · $130,421.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 341 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 341.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dermavant Sciences, Inc. $18.8108/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194207 CMS
Galderma Laboratories, L.P. $20.6508/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059698987 CMS
Dermavant Sciences, Inc. $58.9508/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194199 CMS
Dermavant Sciences, Inc. $82.0008/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194203 CMS
Janssen Biotech, Inc. $16.5707/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182307 CMS
ABBVIE INC. $11.8007/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997386649 CMS
Lilly USA, LLC $1,875.0007/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031333433 CMS
Novartis Pharmaceuticals Corporation $20.9907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992271133 CMS
Sun Pharmaceutical Industries Inc. $35.7307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053831905 CMS
UCB, Inc. $29.1507/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021586271 CMS
ABBVIE INC. $26.9407/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997386647 CMS
E.R. Squibb & Sons, L.L.C. $30.8307/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232123 CMS
GENZYME CORPORATION $33.3807/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049783689 CMS
Janssen Biotech, Inc. $12.6707/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182297 CMS
Lilly USA, LLC $24.0107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031333441 CMS
Dermavant Sciences, Inc. $210.1507/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194169 CMS
Dermavant Sciences, Inc. $466.8007/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194173 CMS
Dermavant Sciences, Inc. $30.9207/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194177 CMS
Dermavant Sciences, Inc. $49.0807/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194181 CMS
Dermavant Sciences, Inc. $68.7707/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194185 CMS
Dermavant Sciences, Inc. $44.5307/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194187 CMS
Dermavant Sciences, Inc. $434.8007/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194191 CMS
Dermavant Sciences, Inc. $99.3207/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194195 CMS
Organon LLC $30.0507/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046754223 CMS
Janssen Biotech, Inc. $64.9507/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182287 CMS
Janssen Biotech, Inc. $19.2307/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182379 CMS
Dermavant Sciences, Inc. $5,400.0007/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194161 CMS
Dermavant Sciences, Inc. $93.0107/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194165 CMS
E.R. Squibb & Sons, L.L.C. $15.3007/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232139 CMS
STRATA Skin Sciences, Inc. $14.5307/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052694579 CMS
E.R. Squibb & Sons, L.L.C. $124.4507/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232155 CMS
E.R. Squibb & Sons, L.L.C. $3,308.0007/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232173 CMS
E.R. Squibb & Sons, L.L.C. $5.0007/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232181 CMS
E.R. Squibb & Sons, L.L.C. $8.8807/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232147 CMS
Dermavant Sciences, Inc. $20.9907/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194157 CMS
Arcutis Biotherapeutics, Inc. $17.4806/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044690273 CMS
UCB, Inc. $34.9806/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021586283 CMS
ABBVIE INC. $23.9106/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997386645 CMS
Dermavant Sciences, Inc. $27.5106/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194153 CMS
LEO Pharma Inc. $14.4906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053477261 CMS
Sun Pharmaceutical Industries Inc. $19.0806/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053831929 CMS
Dermavant Sciences, Inc. $25.1006/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194145 CMS
Dermavant Sciences, Inc. $3,600.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194149 CMS
E.R. Squibb & Sons, L.L.C. $97.2006/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232164 CMS
Janssen Biotech, Inc. $21.9606/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182459 CMS
Lilly USA, LLC $24.0106/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031343535 CMS
Sun Pharmaceutical Industries Inc. $5.6106/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053831925 CMS
E.R. Squibb & Sons, L.L.C. $16.8006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015232131 CMS
Novartis Pharmaceuticals Corporation $7.3506/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992271125 CMS
Dermavant Sciences, Inc. $121.6606/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991194141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,476.37 221
PY2020 $10,621.17 80
PY2021 $34,488.04 97
PY2022 $84,559.89 255
PY2023 $130,421.20 341
PY2024 $125,300.23 372
PY2025 $113,294.19 337

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $35,170.66 30
PY2024 Principal investigator $285,290.72 172
PY2023 Recipient $4,835.00 4
PY2023 Principal investigator $440,477.94 146
PY2022 Recipient $4,351.00 4
PY2022 Principal investigator $773,140.12 102
PY2021 Recipient $6,450.00 3
PY2021 Principal investigator $593,960.20 155
PY2020 Recipient $9,712.36 7
PY2020 Principal investigator $597,327.20 74
PY2019 Recipient $24,182.00 3
PY2019 Principal investigator $769,667.26 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,204.28 11/20/2025 Non-covered Recipient Entity
CUTANEOUS CLINICAL TRIALS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184263433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,125.00 11/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,125.00 11/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288219
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,300.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288005
Principal investigator 1 Novartis Pharmaceuticals Corporation $119.78 10/08/2025 Non-covered Recipient Entity
NORTHEAST DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313757
Principal investigator 1 Eli Lilly and Company $14,164.00 06/25/2025 Non-covered Recipient Entity
CUTANEOUS CLINICAL TRIALS, LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880996
Principal investigator 1 Eli Lilly and Company $5,360.00 04/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187872309
Principal investigator 1 Eli Lilly and Company $2,402.46 03/10/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187874199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $385.00 01/22/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274377
Principal investigator 1 Incyte Corporation $196.10 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498602
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498606
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498610
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498612
Principal investigator 1 Incyte Corporation $196.10 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498616
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498620
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498624
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498628
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498632
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498636
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498640
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498644
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498648
Principal investigator 1 Incyte Corporation $185.50 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498652
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498656
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498660